( 您好!臺灣時間:2022/08/14 02:29
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):Tzu-Chao Chuang
論文名稱(外文):Study on HER2/neu-targeting Cancer Gene Therapy
指導教授(外文):Ming-Ching Kao
中文關鍵詞:神經膠原致癌基因猿病毒腫瘤抗原EB 病毒核抗原-1微脂粒基因治療合併基因治療
外文關鍵詞:HER2/neuSV40LTEBNA1liposomegene therapycombined gene therapy
  • 被引用被引用:3
  • 點閱點閱:631
  • 評分評分:
  • 下載下載:131
  • 收藏至我的研究室書目清單書目收藏:1
文獻報告神經膠原致癌基因的基因調控失常會導致許多惡性腫瘤的產生,若能抑制此致癌基因的表現,即能抑制細胞的轉形、癌化與惡性轉移。因此,神經膠原致癌基因是一個發展抗癌藥物的良好標的。本實驗室即以此為目標,目前已有下列五項成果:第一、發現猿病毒腫瘤抗原氮端部位(LT425)除了能抑制神經膠原致癌基因過度表現的卵巢癌細胞之轉形與癌化作用,同時也是神經膠原致癌基因過度表現的乳癌細胞之轉形與轉移抑制劑;第二、建立卵巢癌腫瘤之裸鼠動物模式,發現利用自製的微脂粒攜帶 LT425 進行神經膠原致癌基因標的基因治療,可達50﹪效果,且安全性高;第三、發現 EB 病毒核抗原-1(EBNA1)能有效抑制神膠原致癌基因之轉錄表現及癌化表徵,其作用機轉與延長 G2/M 細胞週期以及降低抗藥性有關;第四、發現EB 病毒核抗原-1之氮端部位(EBNA1-NT)即能作為神經膠原致癌基因之轉形抑制劑,大幅減低神經膠原致癌基因過度表現的卵巢癌細胞之抗藥性;第五、評估合併 LT425 與 E1A 進行基因治療之可行性。綜合本論文之結果可提供為將來臨床上治療因神經膠原致癌基因過度表現所引發之人類癌症的有益參考資料。
It is known that the deregulation of the HER2/neu oncogene will cause many types of human cancers. Repression of this oncogene expression will suppress the transformation, tumorigenicity and malignant metastasis of the cancer cells. Thus, the HER2/neu oncogene is a good target for developing anti-cancer agents. Our lab has achieved the following five discoveries by making an attemp at approaching this goal. First, the N-terminal domain of the SV40 large T antigen (LT425) may act as HER2/neu-mediated transforming and metastasis suppressor both in ovarian and breast cancers. Second, using the lab-made SP/DOPE-LT425 lipoplex-mediated HER2/neu-targeting approach, 50% of the mice would survive for more than one year in an ovarian tumor-bearing nude mouse model. No significant toxic effects to the mice were observed in the entire lipoplex treated process. Third, the wild-type Epstein-Barr virus nuclear antigen-1 (EBNA1) could inhibit the HER2/neu oncogene expression at the transcriptional level and subsequently repress the HER2/neu-mediated malignant phenotypes. The repression mechanism was proposed to be related to the prolongation of G2/M phase and sensitize the cancer cells to the topoisomerase-IIa-targeting drugs. Fourth, the N-terminal domain only of EBNA1 (EBNA1-NT) could also act as a transforming suppressor of the HER2/neu oncogene. It could sensitize the HER2/neu-overexpressed ovarian cancer cells to anti-cancer drugs. Finally, the possibility of a combined gene therapy approach was evaluated by using LT425 and E1A genes. Taken together, the results of this thesis may provide beneficial evidences of using liposome-mediated HER2/neu-targeting approaches to the human cancer gene therapy.
第一節、研究緣起與目的 ………………………………………………….1
第二節、神經膠原致癌基因與癌症 ………… ……………………………4
第三節、癌症基因治療 ……………………………………………………22
2.1.1. 實驗材料與方法 ……………………………………………………32
2.1.2. 結果與討論 …………………………………………………………36
2.1.3. 結果圖表 ……………………………………………………………41
2.2.1. 實驗材料與方法 ……………………………………………………48
2.2.2. 結果與討論 …………………………………………………………51
2.2.3. 結果圖表 ……………………………………………………………55
的轉形能力並增加抗癌藥物的活性 ………………………………………67
3.1.1. 實驗材料與方法 ……………………………………………………72
3.1.2. 結果與討論 …………………………………………………………78
3.1.3. 結果圖表 ……………………………………………………………82
細胞的G2/M細胞週期並增加對拓普脢 II a 標的藥及Taxol等藥物敏感性
3.2.1. 實驗材料與方法 ……………………………………………………92
3.2.2. 結果與討論 …………………………………………………………96
3.2.3. 結果圖表 …………………………………………………………102
現之卵巢癌細胞的轉形能力並減低抗藥性 ……………………………110
3.3.1. 實驗材料與方法 …………………………………………………110
3.3.2. 結果與討論 ………………………………………………………112
3.3.3. 結果圖表 …………………………………………………………117
第四章:合併性基因治療之評估 ………………………………………126
4.1. 實驗材料與方法 ……………………………………………………127
4.2. 結果與討論 …………………………………………………………130
4.3. 結果圖表 ……………………………………………………………132
第五章:結論 ………………………………………………………………134
參考文獻 ……………………………………………………………………135
Adams, G. P., Schier, R., McCall, A. M., Crawford, R.S., Wolf, E. J., Weiner, L. M., Marks, J. D. (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77:1405—1412.
Adnane, J., Gaudray, P., Simon, M. P., Simony-Lafontaine, J., Jeanteur, P., Theillet, C. (1989) Proto-oncogene amplification and breast tumor phenotype. Oncogene 4:1389—1395.
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K. and Yamanloto, T. (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 232, 1644-1646.
Alaou-Jamali, M. A., Paterson, J., Al Moustafa, A. E. and Yen, L. (1997) The role of erbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem. Cell Biol. 75:315-325.
Albini, A., Iwamoto, Y., Kleinman, H.K., Martin, G.R., Aaronson, S.A., Kozlowski, J.M. and McEwan, R.N. (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47, 3239-3245.
Allred, D.C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., Eudey, L., McGuire, W. L. (1992) HER2/neu in node-negative breast cancer: prognostic signif-icance of overexpression influenced by the presence of in situ car-cinoma. J Clin Oncol 10:599—605.
Ambinder, R. F., Mullen, M. A., Chang, Y. N., Hayward, G. S., and Hayward, S. D. (1991) Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J. Virol. 65, 1466-1478
Amici, A., Smorlesi, A., Noce, G., Santoni,G.,Cappelletti, P., Capparuccia, L., Coppari, R., Lucciarini, R., Petrelli, C. and Provinciali, M. (2000) DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther., 7, 703 -706.
Antoniotti, S., Maggiora, P., Dati, C., De Bortoli, M. (1992) Tamoxifen up-regulates c-erb B-2 expression in oestrogen- responsive breast cancer cells in vitro. Eur J Cancer 28:318—321.
Arguello F, Baggs RB, Eskenazi AE, Duerst RE, Frantz CN. (1991) Vascular anatomy and organ-specific tumor growth as critical fac-tors in the development of metastases and their distribution among organs. Int J Cancer 48:583—590.
Artega, C. L., Winnier, A. R., Poirier, M. C., Lopez-Larraza, D. M., Shawver, L. K., Hurd, S. D. and Stewart, S. J. (1994) p185c-erbB-2 signaling enhances cis-platin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and grug-induced DNA repair. Cancer Res. 54:3758-3765.
Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K. (1997) The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. Cell, 89, 1175-1184
Avantaggiati, M. L., Carbone, M., Graessmann, A., Nakatani, Y., Howard B. and Levine AS. (1996) The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO Journal. 15(9):2236-48.
Bacus, S. S., Huberman, E., Chin, D. et al., (1992) A ligand for the ebb-2 oncogene product (gp30) induce differentiation of human breast cancers. Cell Growth Differ. 3:401-411.
Bacus, S. S., Zelnick, C. R., Plowman, G., Yarden, Y. (1994) Expression of the erbB-2 family of growth factor receptor and their ligands in breast cancers. Am. J. Clin. Pathol. 102 (Suppl 1): S13-S24.
Baer, R., A. T. Bankier, M. D. Biggin, P. L. Deiniger, P. J. Farrell, T. J. Gibson, G. Hatfull, G. S. Hudson, S. C. Satchwell, C. Seguin, P. S. Tuffnell and B. G. Barrell. (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211.
Bagchi, S., Weinmann, R. & Raychauduri, P. (1991) The retinoblastoma protein copurifies with E2F-1, an E1A-regulated inhibitor of the transcription factor E2F. Cell 65, 1063-1072.
Bargmann, C. I., Hung, M. C., Weinberg, R. A. (1986) The neu oncogene encodes an epidermal-growth-factor receptor-related protein. Nature 319:226—230.
Barnes, M. N., Deshane, J. S., Siegal. G. P., Alvarez, R. D. and Curiel, (1996) Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin. Cancer Res. 2:1089-1095.
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twad-dell T, Henderson IC, Norton L. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal an-tibody in patients with HER2/neu-overexpressing meta
Baselga, J., Norton, L., Albanell, J., Kim, Y. M. and Mendelsohn, J. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhance the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825-2831.
Baselga, J., Seidman, A. D., Rosen, P. P. and Norton, L. (1997) HER2 overex-pression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11:43—48.
Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X. M., Yarden, Y., Hynes, N. E. (1995) Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 15:6496—6505.
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M. and Osborne, C. K. (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24:85-95.
Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr., (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087—4091.
Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J, Waterfield, M. D., Groner , B., Hynes, M. E. (1988) Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238—1243.
Bertram, J., Killian, M., Brysch, W., Schligensiepen, K. H. and Kneba, M. (1994) Reduction of c-erbB-2 gene product in mammary carcinoma cell lines by c-erbB-2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucliotides. Biochim. Biophy. Res. Comm. 200, 661-667.
Bieche, I. and Lidereau, R. (1995) Genetic alterations in breast cancer. Genes Chromosomes Cancer 14, 227-251.
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270: 475-480.
Blagosklonny, M. V., Schulte, T., Nguyen, P., Trepel, J. and Neckers, L. M. (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Research. 56(8):1851-4.
Bochkarev, A., Barwell, J. A., Pfuetzner, R. A., Bochkareva, E., Frappier, L. and Edwards, A. M. (1996) Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell. 84, 791-800.
Bochkarev, A., Barwell, J. A., Pfuetzner, R. A., Furey, W., Jr. Edwards, A. M. and Frappier, L. (1995) Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1. Cell. 83, 39-46.
Bordignon, C., Notarangelo, L. D., Nobili, N., Ferrari, G., Casorati, G., Panina, P., Mazzolari, E., Maggioni, D., Rossi, C., Servida, P., et al et al. (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270: 470-475.
Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., Ryden, s. and Sigurdsson, H. (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81:137-144.
Borg, J. P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Adelaide, J., Margolis, B. and Birnbaum, D. (2000) ERBIN; a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat. Cell Biol. 2:407-414.
Bosher, J. M. Williams, T. & Hurst, H. C. (1995) The developmentally regulated transcription factor AP-2 is involved in c-erbB2 overexpression in human mammary carcinoma. Proc. Natl. Acad. Sci. USA 92, 744-747.
Brown, M., McCormack, M., Zinn, K. G., Farrell, M. P., Bikel, I., Livingston, D. M. (1986) A recombinant murine retrovirus for simian virus 40 large T cDNA transforms mouse fibroblasts to anchorage-independent growth. Journal of Virology. 60(1):290-3.
Burden, S., Yarden, Y. (1997) Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18: 847-55.
Burke, H. B., Hoang, A., mIglehart, J. D. and Marks, J. R. (1998) Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 82:874-877.
Burns, J. C., Friedmann, T., Driever, W., Burrascano, M and Yee, J. K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and non-mammalian cell. Proc. Natl. Acad. Sci. USA 90:8033-8037.
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R. and Soltoff, S. (1991) Oncogenes and signal transduction. Cell 64, 281-302.
Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Mora-bito A, Pettinato G, Panico L, D’Antonio A, Bianco AR, De Placido S. (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702—2708.
Carraway III, K. L., Rossi, E.A., Komatsu, M., Price-Schiavi, S. A., Huang, D., Guy, P. M., Carvajal, M. E., Fregien, N., Carraway, C. A. A. and Carraway, K. L. (1999) An intramembrane ErbB2/Neu ligand that potentiates neuregulin signaling. J. Biol. Chem. 274: 5263-5266.
Carraway KL III, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C. (1997) Neuregulin-2, a new ligand of ErbB3/ErbB4-recep-tor tyrosine kinases. Nature 387:512—516.
Carraway, K. L. III., and Cantley, L. C. (1994) A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5—8.
Carraway, K. L., Price-Schiavi, S. A., Komatsu, M., Idris, N., Perez, A., Li, P., Jepson, S., Zhu, X., Carvajal, M. E. and Carraway, C. A. C. (2000) Multiple facets of sialomucin complex/Muc4, a membrane mucin and ErbB2 ligand, in tumors and tissues. Front. Biosci. 5: 95-107.
Carter, P. J. and Samulski, R. J. (2000) Adeno-associated viral vectors as gene delivery vechicles. Int. J. Mol. Med. 6: 17-27.
Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., Bousso, P., Deist, F. L., Fischer, A.., et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-Xl disease. Science 288: 669-672.
Challberg, M. D and Kelly, T. J. (1989) Animal virus DNA replication. Ann. Rev. Biochem.,58: 671-717.
Chen, H. and Hung, M. C. (1997) Involvement of co-activator p300 in the transcriptional regulation the HER-2/neu gene. J Biol. Chem. 272, 6101-6104.
Chen, J. Y. Chen, C. J., Liu, M. Y., Cho, S. M., Hsu, M. M., Lynn, T. C., Shieh, T., Tu, S. M., Lee, H. H., Kuo, S. L., et al., (1987) Antibodies to Epstein-Barr virus-specific DNase in patients with nasopharyngeal carcinoma and control groups. J Med Virol. 23(1):11-21.
Chen, J. Y., Chen, C. J., Liu, M. Y., Cho, S. M., Hsu, M. M., Lynn, T. C., Shieh, T., Tu, S. M., Beasley, R. P. Hwang, L. Y. et al., (1989) Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J Med Virol. 27(4):269-73.
Chen, J. Y., Liu, M. Y., Chen, C. J., Hsu, M. M., Tu, S. M., Lee, H. H. Kuo, S. L., Yang, C. S. (1985) Antibody to Epstein-Barr virus-specific DNase as a marker for the early detection of nasopharyngeal carcinoma. J Med Virol. 17(1):47-9.
Chien, Y. C., Chen, J. Y., Liu, M. Y., Yang, H. I., Hsu, M. M., Chen, C. J. and Yang, C. S. (2001) Serologic Markers of Epstein—Barr Virus Infection and Nasopharyngeal Carcinoma in Taiwanese Men. The New England Journal of Medicine: 345 (26) 1877-1882.
Chirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., Wilson, J. M. (2000) Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Viro. 74: 2420-2425.
Chiu, F. L. (1999) Repression of transforming effect of the HER2/neu oncogene by the N-terminal domain of the EBNA1 in breast cancer cells. Master thesis (adviser: Kao, M. C.), National Defense Medical Center, Taipei, Taiwan.
Chuang, T. C. (1996) Develop a novel liposome-mediated gene delivery system and analysis of repression of neu oncogene by mutant SV40 large T antigen. Master thesis (adviser: Kao, M. C. and Law, S. L.), National Defense Medical Center, Taipei, Taiwan.
Chuang, T. C., Hu, C. L., Lin, Y. S., Law, S. L., and Kao, M. C. (2002c) Mapping of EBNA1 domains responsible for suppression of HER2/neu-mediated transformation via transcriptional repression of HER2/neu. (To be submitted)
Chuang, T. C., Lin, Y. S., Law, S.L. and Kao, M. C. (2002d) EBNA1 may prolong G2/M phase and sensitizes to topoisomerase II-targeting and paclitaxel anticancer drugs in HER2/neu-overexpressing ovarian cells. (To be submitted)
Chuang, T. C., Way, T. D., Lin, Y. S., Law, S. L. and Kao, M. C. (2001b) Suppression of the HER2/neu-mediated transformation by the Epstein-Barr virus nuclear antigen-1. (Submitted to J. Biol. Chem.)
Chuang, T. C., Yu, Y. H., Lin, Y. S., Wang, S. S. and Kao, M. C. (2001a) The N-terminal domain of SV40 Large T antigen represses the HER2/neu-mediated transformation and metastatic potential in breast cancers. FEBS Lett. (in press)
Clark GM. (1998) Should selection of adjuvant chemotherapy for pa-tients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 90:1320—1321.
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Paton, V., Shak, S., Lieberman, G. and Slamon, D. (1998) Efficacy and safety of Herceptin (Humanized anti-HER2 antibody) as a single agent in 222 woman with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 17:97A.
Colomer, R., Montero, S., Lluch, A., Ojeda, B., Barnadas, A., Casado, A., Massuti, B., Cortes-Funes, H. and Lloveras, B. (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clinical Cancer Research. 6(6):2356-62.
Colomer, R., Montero, S., Lluch, A., Ojeda, B., Barnadas, A., Casado, A., Massuti, B., Cortes-Funes, H. and Lloveras, B. (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res. 6: 2356-2362.
Conzen, S. D., Snay, C. A. and Cole, C. N. (1997) Identification of a Novel antiapoptotic Functional Domain in Simiun Virus 40 large T antigen . J Virol 71 :4536-4543.
Coussen, L., Yang-Feng, T. L. and Liao, Y. C. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230, 1132-1139.
Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J. and Francke, U. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-9.
Craft, N., Shostak, Y., carey, M. and Sawyers, C. L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER2/neu tyrosine kinase. Nat. Med. 5:280-285.
Crovello, C. S. and Carraway, K. L. III (2001) Specificity in growth factor signaling through localization and modulation of ErbB receptor tyrosine kinase. Curr. Opin. Cell Biol. 13: 125-130.
D’souza, B. and Taylor-Papdimitriou, J. (1994) Overexpression of erbB-2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc. Natl. Acad. Sci. USA 91,7202-7206.
Dai, Y., schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N. & Verma, I. (1995) Cellular and Humoral immune responses to adenoviral vectors containing factor IX and vectorantigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92, 1401-1405.
Daly, J. M., Olayioye, M. A., Wong, A. M., Neve, R., Lane, H. A., Maurer, F. G., Hynes, N. E. (1999) NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene 18:3440—3451.
Dankort, D., Jeyabalan, N., Jones, N., Dumont, D. J., Muller, W. J. (2001) Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. J. Biol. Chem. 276(42):28921-8.
Danos, O. and Mulligan, R. C. (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85:6460-6464.
Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., De Bortoli, M. (1990) Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5:1001—1006.
Debbas, M. & White, E. (1993) Wild type p53 mediates apoptosis by E1A, which is inhibited by E1B. Gene Dev. 7, 546-554.
DeCaprio, J. A. Ludlow, J. W., Figge, J., Shew, J. Y., Huang, C. M. Lee, W. H., Marsolio, E., Paucha, E. & Livingston, D. M. (1988) SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54,275-283.
D''Emilia, J., Bulovas, K., D''Ercole, K., Wolf, B., Steel, G. Jr., and Summerhayes, I. C. (1989) Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 4, 1233-1239.
Deo, Y. M., Granziano, R. F., Repp, R., van de Winkel, J. G. (1997) Clinical significance of IgG Fc receptors and Fc gamma R-directed immu-notherapies. Immunol Today 18:127—135.
Deshane, J., Cabrera, G., Grim, J. E., Siegal, G. P., Pike, J., Alvarez, R. D., Curiel, D. T. (1995b) Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecologic Oncology. 59(1):8-14..
Deshane, J., Grim, J., Loechel, S., Siegal, G. P., Alvarez, R. D., Curiel, D. T. (1996) Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Therapy. 3(2):89-98.
Deshane, J., Siegal, G. P., Alvarez, R. D., Wang, M. H., Feng, M., Cabrera, G., Liu, T., Kay, M., Curiel, D. T. (1995a) Targeted tumor killing via an intracellular antibody against erbB-2. Journal of Clinical Investigation. 96(6):2980-9.
Dickman, S. (1998) Antibodies stage a comeback in cancer treatment. Science 280:1196-1197.
Dobson, A. T., Margolis, T. P., Sedarati, J. G. & Feldman, L. T. (1991) A latent non-pathogenic HSV-derived vector stably expresses b-galactosidase in mouse neurans. In Miami Short Reports-Advance in Gene Technolngy: The Molecular Biology of Human Genetic Disease. vol 1. Boehringer Mamnheim Biochimicals.USA, 1991. p43.
Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffild, M., Moon, R., Bacher, J., Zsebo, K. M. & Nienhuis, A. W., Nienhuis. (1992) Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125-1135.
Dougall, W. C., Qian, X., Peterson, N. C. Miller, M. J. Samanta, A. & Greene, M. I. (1994) The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9, 2109-2123.
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Kevitsky, H., Brose, K. Jackson, V. Hamada, H., Pardoll, D. & Mulligna, R. C. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulation factor stimulates potent, specofic and olng-lasting anti-tumor immunity. Porc. Natl. Acad. Sci. USA 90, 3539-3543.
Drebin, J. A., Link, V. C. and Greene, M. I. (1988a) Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2: 387-394.
Drebin, J. A., Link, V. C., Greene, M. I. (1988b) Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene. 2(3):273-7.
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A. and Greene, M. I. (1985) Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706.
Drebin, J. A., Link, V. C., Weinberg, R. A., Greene, M. I. 91986) Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA. 83(23):9129-33.
Dsly, R. J.Binder, M. D. and Sutherland, R. L. (1994) Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9, 2723-2727.
Dyson, N., Howley, P. M., Munger, K. and Harlow, E. (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-937.
Earp, H. S., Dawson, T. L., Li, D. X., Yu, H. (1995) Heterodimerization and functional interaction between EGF receptor family membranes: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 35:115-132.
Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., DeCaprio, J. A., Lawrence, J. B. and Livingston, D. M. (1994) Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes & Development. 8(8):869-84.
Eckner, R., Ludlow, J. W., Lill, N. L., Oldread, E., Arany, Z., Modjtahedi, N., Decaprio, J. A., Livingston, D. M. and Morgan, J. A. (1996) Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol., 16, 3454-3464.
Epstein, R. J., Druker, B. J., Roberts, T. M. & Stiles, C. D. (1990) Modulation of Mr 175,000 c-neu receptor isoform in G8/DHFR cells by serum starvation. J. Biol. Chem. 18, 10746-10751.
Fahraeus, R., Fu, H. L., Ernberg, I., Finke, J., Rowe, M., Klein, G., Falk, K., Nilsson, E., Yadav, M., Busson, P. (1988) Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. International Journal of Cancer. 42(3):329-38.
Fanning, E. and Knippers, R. (1992) Structure and function of simian virus 40 large tumor antigen. Ann. Rev. Biochem. 61, 55-85.
Fehm, T., Maimonis, P., Katalinic, A. and Jager, W. H. (1998) The prognostic siginificance of c-erbB-2 serum protein in metastasic breast cancer. Oncology 55:33-38.
Fehm, T., Maimonis, P., Weitz, S., Teramoto, Y., Katalinic, A. and Jager, W. (1997) Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res. Treat. 43:87-95.
Felgner, P. L. and Ringold, G.M. (1989) Cationic liposome-mediated transfection. Nature 337, 387-388
Fenjves, E. S., Gorson, D. A., Pershing, L. K., Williama, D. L. & Taichman, L. B. (1989) Systemic distribution of apolipoprotein E secreted by grafts of epidermal keratinocytes : Implication for epidermal function and gene therapy. Proc. Natl. Acad. Sci. USA 86, 8803-8807.
Fiers, W., Contreras., Haegemen, R., Rogiers, R., Voorde, V., Heuverswyn, H. V., Herreweghe, J. V., Volckaert, G. & Ysebaert, M. (1978) Complete nucleotide sequence of SV40 DNA. Nature 273, 113-120.
Frappier, L. and Goldsmith, K. and Bendell, L. (1994) Stablization of the EBNA1 protein on the Epstein-Barr virus latent origin of DNA replication by a DNA looping mechanism. J Biol. Chem. 269, 1057-1062.
Frappier, L., Goldsmith, K. and Bendell, L. (1994) Stabilization of the EBNA1 protein on the Epstein-Barr Virus latent origin of DNA replication by a DNA looping mechanism. J Biol. Chem. 378, 390-394
Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S and Dobrusin EM. (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA, 95, 12022 -12027.
Fujiwara, T., Grimm, E. A. Mukhopadhyay, T., Zhang, W. W., Owen-Schauub, L. B. & Roth, J. A. (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild type p53 gene. Cancer Res. 54, 2287-2291.
Fukushige, S. I., Matsubara, K. I., Yoshida, M., Sasaki, M., Suzuki, T., Semba, K., Toyoshima, K. and Yamamoto, T. (1986) Locolization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol. Cell. Biol. 6: 955-958.
Gannon, J. V. and Lane, D. P. (1987) p53 and DNA polymerase alpha compete for binding to SV40 T antigen.. Nature 349: 802-806.
Gao, X. & Huang, L. (1991) A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 179, 280-285.
Gassmann, M., Casagranda, F. Orioll, D. Simon, H. Lai, C. Klein, R. & Lemke, G. (1995) Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390-394.
Gee, J. E. Yen, R. L., Hung M. C. & Hogan, M. E. (1994) Triple formation at the rat neu oncogene promoter. Gene 149, 109-114.
Giani, C., Casalini, P., Pupa, S. M., De Vecchi, R., Ardini, E., Colnaghi, M. I., Giordano, A., Me´nard, S. (1998) Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 17:425—432.
Giannois, J. and Ioannidou-Mouzaka, L. (1997) Molecular aspects of breast and ovarian cancer. Eur. J. Gynaecol. Oncol. 18:387-393.
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deleage, G., Hallek, M. (1999) Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nature Med. 5: 1052-1056.
Goldsmith, K., Bendell, L. and Frappier, L. (1993) Identification of EBNA1 amino acid sequences required for the interation of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J. Virol. 67, 3418-3426.
Gorman, C. M. Merlino, G. T. Willingham, M. C., Pastan I. & Howard, B. H. (1982) The rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc. Natl. Acad. Sci. USA 79, 6777-6781.
Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2, 1044-1051
Goto, S., Ihara, Y., Urata, Y., Izumi, S., Abe, K., Koji, T. and Kondo, T. (2001) Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase. FASEB J. 15(14):2702-14.
Gotoh, N., Tojo, A., Muroya, K., Hashimoto, Y., Hattori, S., Nakamura, S., Tskenawa, T., Yazaki, Y. & Shibuya, M. (1994) Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity. Proc. Natl. Acaad. Sci. USA 91, 167-171.
Graham, F. L., and van der Eb, A. J. (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virolog 52, 456-467
Graus-Porta, D. Beerli, R. R., Daly, J. M., Hynes, N. E. (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO Journal. 16(7):1647-55.
Graus-Porta, D., Beerli, R. R., Hynes, N. E. (1995) Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differenti-ation factor and epidermal growth factor signaling. Mol Cell Biol 15:1182—1191.
Grunt, T., Dittrich, E., Ofterdinger, M., Schneider, S. M., Dittrich, C. and Huber, H. (1998) Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br. J. Cancer 78:79-87.
Gu, K., Mes-Masson, A. M., Gauthier, J. and Saad, F. (1996) Overexpression of HER-2/neu in human prostate cancer and begin hyperplasia. Cancer Lett. 99, 185-9.
Gullick, W. J. (1990) The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int. J. Cancer, Suppl 5, 55-61.
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Sa¨ ve-So¨derborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bu¨ rki K, Castiglione M, Collins J, Lindtner J, Senn HJ. (1992) Prognostic importance of c-erb B-2 expression in breast cancer. J Clin Oncol 10:1049—1056.
Guy, C.T. Webster, M.A., Schaller, M., Parson, T.J., Cardiff, R.D. and Muller, W.J. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89, 10578-10582.
Halbert, C. L., Rutledge, E. A., Allen, J. M., Russel, D. W. and Miller, A. D. (2000) Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Viro. 74:1524-1532.
Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P. and Shawver, L. K. (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloro-platinum against human breast and ovarian tumor cell lines. Cancer Res. 51:4547-4580.
Hara, T., Aramaki, Y., Takada, S., Koike, K., Tsuchiya, S. (1995) Receptor-mediated transfer of pSV2CAT DNA to a human hepatoblastoma cell line HepG2 using asialofetuin-lab- eled cationic liposome. Gene 159: 167—174.
Harris, J. D., Gutierrez, A. A., Hurst, C. C., Sikora, K. and Lemoine, N. R. (1994) Gene therapy for cancer using tumour-specific prodrug activation. Gene Therapy, 1, 170 -175.
Harris, L. N., Yang, L., Liotcheva, V., Pauli, S., Iglehart, J. D., Colvin, O. M., Hsieh, T. S. (2001) Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Cancer Res. 7(6): 1497-504.
Haynes, N. M., Smyth, M. J., Kershaw, M. H., Trapani, J. A. and Darcy, P. K. (1999) Fas-ligand-mediated lysis of erbB-2-overexpressing tumor cells by redirected cytotoxic T lymphocytes. Cancer Immunol. Immunother. 47: 278-286.
Hazan, R., Margolis, B., Dombalagian, M., Ullrich, A., Zilberstein, A. and Schlessinger, J. (1990) Identification of autophosphoylation sites of HER-2/neu. Cell. Growth. Differ. 1, 3-7.
Hearing, J. C. and Levine, A. J. (1985) The Epstein-Barr virus nuclear antigen (BamHI K antigen) is a single-strand DNA binding phosphoprotein. J. Virol. 145, 105-116.
Hellyer, N. J., Kim, M. S., Koland, J. G. (2001) Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J. Biol. Chem. 276(45): 42153-61.
Hollywood, D. P. & Hurst, H. C. (1993) A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB2 in mammary tumor lines. EMBO J. 12,2368-2375.
Holmes WE, Sliwkowski MX, Akita RW, Hinzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Sgepard HM, Kuang WJ, Wood WI, Goeddel DV & Vandlen RL. (1992) Identification of Heregulin, a specific activator of p185erbB2. Science 256: 1205-1210.
Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Hinzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., Sgepard, H. M., Kuang, W. J., Wood, W. I., Goeddel, D. V. & Vandlen, R. L. (1992) Identification of Heregulin, a specific activator of p185erbB2. Science 256, 1205-1210.
Hong, R. L., Spohn, W. H. and Humg, M. C. (1999) Curcumin inhibits tyrosine-kinase activity of p185neu and also seplets p185neu after dissociating it from GRP941. Clin. Cancer Res. 5:1884-1891.
Horan T, Wen J, Arakawa T, Liu NL, Brankow D, Hu S, Ratzkin B, Philo JS. (1995) Binding of neu differentiation factor with the extracellular domain of Her2 and Her3. J Biol Chem 270:24604—24608.
Hortobagyi GN. Ueno NT. Xia W. Zhang S. Wolf JK. Putnam JB. Weiden PL. Willey JS. Carey M. Branham DL. Payne JY. Tucker SD. Bartholomeusz C. Kilbourn RG. De Jager RL. Sneige N. Katz RL. Anklesaria P. Ibrahim NK. Murray JL. Theriault RL. Valero V. Gershenson DM. Bevers MW. Huang L. Lopez-Berestein G. Hung MC. (2001) Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. Journal of Clinical Oncology. 19(14):3422-33.
Hortobagyi, G. N., Carey, M. M., Hung, M-C., and Lopez, G. A (1998) Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER2/neu or epithelial ovarian cancer. Hum. Gene Ther., 9: 1775—1798.
Hou, L., Shi, D., Tu, S. M. (1992) Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett. 65: 215-220.
Hu, C. L. (1998) The N-terminal 86-amino-acid domain of the EBNA1 may act as a transforming suppressor of the HER2/neu oncogene. Master thesis (adviser: Kao, M. C.), National Defense Medical Center, Taipei, Taiwan.
Huang, L. H. (1995) Gene Therapy In “Biotechnology”, edited by Tian, W. C., Jiu-Zhou Publisher, Taipei, Taiwan, pp. 319-339.
Huber, B. E., Richards, C. A. & Krenitsky, T. A. (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An inovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88, 8039-8043.
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., Ullrich, A. (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular & Cellular Biology. 9(3):1165-72.
Hug, P. & Sleight, R. G. (1991) Liposomes for the transformation of eukariotic cells. Biochim. Biophys. Acta 1097, 1-17.
Hung, M. C., Schechter, A. L., Chevrary, P. Y. M., Stern, D. F. and Weinberg, R. A. (1986b) Molecular cloning of the neu gene: absence of gross structure alteration in oncogenic alleles. Proc. Natl. Acad. Sci. USA 83: 261-264.
Hung, M. C., Schechter, A. L., Vaidyanathan, L., Stern, D. F. and Weinberg, R. A. (1986a) Isolation of the molecular clone of the neu oncogene from the B103 rat neuro/glioblastoma cell line, p. 391-395. In C.C. Harris (Ed.), Biochemical and Molecular Epidemiology of Cancer. Liss, New York.
Hung, M. C., Wang, S. C., and Hortobagyi, G. N. (1999) Targeting HER-2/neu overexpressing cancer cells with transcriptional repressor genes delivered by cationic liposome. In: L. Hung, M-C. Hung, and E. Wagner (eds.), Cancer Gene Therapy using Cationic Liposome: Preclinic and Clinic Studies, pp. 357—377. San Diego: Academic Press, 1999.
Hung, M. C., Yan, D. H. and Zhao, X. (1989) Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. Proc. Natl. Acad. Sci. USA 86, 2545-2548.
Hung, M. C., Zhang, X., Yan, D. H., Zhang, H. Z., He, G. P., Zhang, T. Q. and Shi, D. R. (1992) Aberrant expression of the c-erbB-2/neu protooncogene in overian cancer. Cell. 62, 1165-1175.
Hunter, T. (1997) Oncoprotein networks. Cell. 88: 333-346.
Huston, J. S., McCartney, J., Tai, M. S., Mottola-Harshorn, C., Jin, D., Warren, F., Keck, P., and Oppermann, H. (1993) Medical applications of single-chain antibodies. Int. Rev. Immunol. 10:195-217.
Inoue, N., Harada, S., Honma, T., Kitamura, T. and Yanagi, K. (1991) The domain of Epstein-Barr virus nuclear antigen 1 essential for binding to oriP region has a sequence fitted for the hypothetical basic-helix-loop-helix structure. J. Virol. 182, 84-93.
Jacquemier, J., Penault-Llorca, F., Viens, P., Houvenaeghel, G., Hassoun, J., Torrente, M., Adelaide, J. and Birnbaum, D. (1994) Breast cancer response to adjuvant chemotherapy in correlation with erB2 and p53 expression. Anticancer Res. 14:2773-2278.
Janes, P. W., Daly, R. J., Fazio, A. & Sutherland, R. L. (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9, 3601-3608.
Janknecht R, Hunter T. (1996) A growing coactivator network. Nature 384(6595): 22-3
Jarvinen, T. A., Holli, K., Kuukasjarvi, T. and Isola, J. J. (1998) Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer 77:2267-2273.
Jones, F. E. and Stern, D. F. (1999) Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18: 3481-3490.
Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. (1991) Association of c-erb B-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650—655.
Kameda, T., Yasui, W., Yoshida, K., Tsujino, T., Nakyama, H., Ito, M., Ito, H. & Tahara, E. (1990). Expression of ERBB2 in human gastric carcinomas: Relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 50, 8002-8009.
Kao, M. C., Law, S. L., Chuang, T. C. and Lin, Y. S. (1998b) in virto gene transfer in mammalin cells via a neu cationic liposome formulation. Oncology reports. 5, 625-9.
Kao, M. C., Liu, G. Y., Chuang, T. C., Lin, Y. S., Wuu, J. A. and Law, S. L. (1998a) The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. Oncogene. 16, 547-554.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X. M., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., Yarden, Y. (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254—264.
Kern, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Green, M. t., Torney, I. and Robinson, R. A. (1990) p185neu expression in human lung adenocarcinomas predicts shortermed survial. Cancer Res. 50, 5184-5191.
Kieff, E. and Liebowitz, D. (1990) Epstein-Barr virus and its replication. Virology. 2, 1889-1920.
King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. (1988) EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J 7:1647—1651.
King, C. R., Kraus, M. H., Aaronson, S. A. (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 947-976.
King, C. R., Swain, S. M. Porter, L., Steinberg, S. M., Lippman, M. E and Gelman, E. P. (1989) Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res. 1;49(15):4185-91.
Kita, Y. A., Barft, J., Luo, Y., Wen, D., Brankow, D., Hu, S., Liu, N., Prigent, S. A., Gullick, W. J. and Nicolson, M. (1994) NDF/heregulin Stimulates the phosphorylation of HER3/erbB3. FEBS Letters. 349, 139-143.
Klapper, L. N., Kirschbaum, M. H., Sela, M. and Yarden, Y. (2000) Biochemical and clinical implications of the ErbB2/HER signaling network of growth factor receptors. Adv. Cancer Res. 77; 25-79.
Kochanek, S. et al. (1996) A new adenovial vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and b-galactosidase. Proc. Natl. Acad. Sci. USA 93; 5731-5736.
Kokai, Y., Cohen, J. A., Drebin, J. A., and Greene, M.I. (1987) Stage- and tissue-specific expression of the neu oncogene in rat development. Proc. Natl. Acad. Sci. USA 84: 8498-8501.
Kokai, Y., Myers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K., Greene, M. I. (1989) Synergistic interaction of p185 c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287—292.
Komatsu, M., Carraway, C. A., Fregien, N. L. and Carraway, K. L. (1997) Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex. Journal of Biological Chemistry. 272(52):33245-54.
Komatsu, M., Jepson, S., Arango, M. E., (2001) Carothers Carraway CA. Carraway KL. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene. 20(4):461-70.
Komatsu, M., Yee, L. and Carraway, K. L. (1999) Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Research. 59(9):2229-36.
Kominsky, S. L., Hobeika, A. C., Lake, F. A., Torres, B. A., Johnson, H. M. (2000) Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Research. 60(14):3904-8.
Kotin, R. M. et al., (1990) Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87:2211-2215.
Kraus, M. H., Issing, W., Miki, T., Popescu, N. C. and Aaronson, S. A. (1989) Isola-tion and characterization of erbB3, a third member of the erbB/ epidermal growth factor receptor family: evidence for overexpres-sion in a subset of human mammary tumors. Proc Natl Acad Sci USA 86:9193—9197.
Kriegler, M., Perez, C. F., Hardy, C., Botchan, M. (1984) Transformation mediated by the SV40 T antigens: separation of the overlapping SV40 early genes with a retroviral vector. Cell. 38(2):483-91.
Kuo, C. Y. (1999) Establishment of an animal model for liposome-mediated HER2 oncogene by EBNA1. Master thesis (adviser: Kao, M. C.), National Defense Medical Center, Taipei, Taiwan.
Lachman, L. B., Rao, X. M., Kremer, R. H., Ozpolat, B., Kiriakova, G., Price, J. E. (2001) DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther. 8(4): 259-68.
Lacroix H., Iglehart, J. D., Skinner, M. A. and Kraus, M. H. (1989) Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene. 4(2):145-51.
Lacroix, H., Iglehart, J.D., Skinner, M.A. and Kraus, M.H. (1989) Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4, 145-51.
Law, S. L., Kao, M. C. & Chuang, T. C. (2000) Formulation of transfection reagent of sphingosine and dioleoylphosphatidylethanolamine. (patent of ROC, No. 114360)
Lee, K. F., Simon, H., Chen, H., Bastes, B., Hung, M. C. & Hauser, C. (1995) Reguirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398.
Lee, Y. C. (1998) Cis-acting element involved in the repression of the HER2/neu oncogene expression by EBNA1. Master thesis (adviser: Kao, M. C.), National Defense Medical Center, Taipei, Taiwan.
Leitzel K, Teramoto Y, Konrad K, Chinchilli V M, Volas G, Grossberg H, Harvey H, Demers L, Lipton A. (1995) Elevated serum c-erb B-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129—1135.
Leone, A., Flatow, U., King, C.R., Sandeen, M.A., Margulies, I.M.K., Liotta, L.A. and Steeg, P.S. (1991) Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 65, 25-35.
Levkowitz, G., Oved, S., Klapper, L. N., Harari, D., Lavi, S., Sela, M., Yarden, Y. (2000) c-Cbl is a suppressor of the neu oncogene. Journal of Biological Chemistry. 275(45):35532-9.
Li, P.. Arango, M. E., Perez, R. E., Reis, C. A., Bonfante, E. L., Weed, D. and Carraway, K. L.. (2000) Expression and localization of immunoreactive-sialomucin complex (Muc4) in salivary gland. Tiss. Cell 33: 111-118.
Lichtenstein, A., Berenson, J., Gera, J. F., Waldburger, K., Martinez-Maza, O., Berek, J. S. (1990) Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Research. 50(22):7364-70.
Lill NL, Grossman SR, Ginsberg D, DeCaprio J and Livingston DM. (1997a) Binding and modulation of p53 by p300/CBP coactivators. Nature, 387: 823-827.
Lill, N. L., Tevethia, M. J., Eckner, R., Livingston, D. M. and Modjtahedi, N. (1997b). p300 family members associate with the carboxyl terminus of simian virus 40 large tumor antigen. J Virol., 71: 129-137.
Lim, H., Das, S. K. and Dey, S. K. (1998) erbB genes in the mouse uterus: cell-specific signaling by epidermal growth factor (EGF) family of growth factors during implantation. Developmental Biology. 204(1):97-110.
Lin, C. T., Chen, W., Hsu, M. M., Dee, A. N. (1997) Clonal versus polyclonal Epstein-Barr virus infection in nasopharyngeal carcinoma cell lines. Laboratory Investigation. 76(6):793-8.
Lin, C. T., Dee, A. N., Chen, W., Chan, W. Y. (1994) Association of Epstein-Barr virus, human papilloma virus, and cytomegalovirus with nine nasopharyngeal carcinoma cell lines. Laboratory Investigation. 71(5):731-6.
Lin, C. T., Kao, H. J., Lin, J. L., Chan, W. Y., Wu, H. C., Liang, S. T. (2000) Response of nasopharyngeal carcinoma cells to Epstein-Barr virus infection in vitro. Laboratory Investigation. 80(8):1149-60.
Lin, Y. C., Peng, J. M. and Wang, W. B. (2000) The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. Oncogene. 19(22):2704-13.
Lin, Y. S., Chuang, T. C., Law, S. L. and Kao, M.C. (2002) An animal model for the HER2/neu-targeting gene therapy by the N-terminal domain of SV40LT (LT425). (To be submitted)
Lin, Y.C., Peng, J.M. and Wang, W.B. (2000) Oncogene, 19, 2704-13.
Liotta, L. A., Steeg, P. S. and Stetler-Stevenson, W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
Liu Y, El-Ashry D, Chen D, Ding IYF, Kern FG. (1995) MCF-7 breast cancer cells overexpressing transfected c-erb B-2 have an in vitro growth advantage in estrogen- depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97—117.
Liu, G. Y. (1995) Transcriptional repression of the neu oncogene by two peptides derived from the SV40 large T antigen. Master thesis (adviser: Kao, M. C.), National Defense Medical Center, Taipei, Taiwan.
Logan, J. J., Bebok, Z., Walker, L. C., Peng, S., Felgner, P. L., Siegal, G. P., Frizzell, R. A., Dong, J., Howard, M., et al. (1995) Cationic lipids for receptor gene and CFTR trans-fer to rat pulmonary epithelium. Gene Therapy 2: 38—49.
Loveland, B. E., Johns, T. G., Mackay, I. R., Vaillant, F., Wang, Z. X., Hertzog, P. J. (1992) Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem. Intern. 27, 501-510.
Mackey, D., Middleton, T. and Sugden, B. (1995) Multiple region within EBNA1 can link DNAs. J. Virol. 69, 6199-6208.
Malik, P., McQuiston, S. A., Yu, X. J., Pepper, K. A., Krall, W. J., Podsakoff, G. M., Kurtzman, G. J., Kohn, D. B. (1997) Recombinant adeno-associated virus mediated a high level of genre transfer but less efficient integration in the K562 human hematopoietic cell line. J. Virol. 71: 1776-1783.
Mandel, H. G. (1995) Thermal instability of chloramphenicol acetyltransferase: assay revisions required. Anal. Biochem, 230, 191-193
Manfredi, J. J. & Prives, C. (1994) The transforming activity of Simian Virus 40 largy tumor antiagen. Biochimica et Biophysica Acta. 1198, 65-83.
Marchionni, M. A. (1995) neu tack on neurequlin. Nature 378, 334-335.
Marchionni, M. A., Goodeari, A. D. J., Chen, M. S., Bermingham-Mc Donogh, O., Sudhalter, J., Kobayashi, K., Wroblewski, D., Lynch, C., Baldassare, M., Hiles, I., Davis, J. B., Hsuan, J. J., Totty, N. F., Otsu, M., McBurney, R. N., Waterfield, M. D., Stroobant, P. & Gwynne, D. (1993) Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362, 312-318.
Margolis, B. L., Lax, I. and Kris, R. (1989) All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER-2/neu are localed in their carboxyl-terminal tails. J. Biol. Chem. 264, 10667-10671.
Marshall, C. J. (1995). Specificity of receptor tirosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179—185.
Matin A and Hung MC. (1993) Negative regulation of the Neu promoter by the SV40 large T antigen. Cell Growth & Differentiation 4: 1051-1056
Matin, A. and Hung, M. C. (1994) The retinoblastoma gene product, Rb, represses neu expression through two regions within the neu regulatory sequence. Oncogene 9, 1333-1339.
Matin, A., Xie, Y., Kao, M. C. & Hunag, M. C. (1995) Rodent p53 suppersses the transforming activity of the activated neu oncogene by modulating the basal promoter activity of neu. International J. Oncol. 6, 1087-1092.
Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K, Yamamoto T. (1993) 17b-Estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc Natl Acad Sci USA 90:10803— 10807.
McCann AH, Dervan PA, O’Regan M. (1991) Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res. 51: 3296-3303.
Me´nard, S., Tagliabue, E., Campiglio, M. and Pupa, S. M. (2000). Role of HER2 gene overexpression in breast carcinoma. J. Cellul. Physiol. 182: 150-162.
Meden, H., Marx, D., Roegglen, T., Schauer, A., and Kuhn, W. (1998) Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in pateins with ovarian cancer. Int. J. Gynerol. Pathol. 17:61-65.
Menard, S., Valagussa, P., Pilotti, S., Gianni, L., Biganzoli, E., Boracchi, P. ,Tomasic, G., Casalini, P., Marubini, E., Colnaghi, M. I., Cascinelli, N. and Bonadonna, G. (2001) Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. Journal of Clinical Oncology. 19(2):329-35.
Mizuguchi, G., Kanei-Ishii, C., Tokahashi, T., Yasulawa, T., Nagase, T., Horikoshi, N., Yamamoto, T. & Ishii, S. (1995) c-Myb repression of c-erbB2 Trans cription by direct binding to the c-erbB2 promoter. J. Biol. Chem. 270, 9384-9389.
Moasser, M. M., Basso, A., Averbuch, S. D., Rosen, N. (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cance Res. 61(19): 7184-8.
Molina, H., Brenner, C., Jacobi, S., Gorka, J., Carel, J. C., Kinoshita, T., Holers, V. M. (1991) Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. Journal of Biological Chemistry. 266(19):12173-9.
Monier R. (1986) The Papovaviridae. Salzman NP. (Ed.). pp.247-294, Plenum Press, New York.
Moran E. (1988) A region of SV40 large T antigen can substitute for a transforming domain of the adenovirus E1A products. Nature, 334: 168-170.
Morgan, R. A. and Anderson, W. F. (1993) Human gene therapy. Ann. Rev. Biochem. 62: 191-217.
Morral, N., O''Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Cordova, E., Wadsworth, S., Graham, F. L., Kochanek, S., Carey, K. D., Beaudet, A. L. (1999) Administration of helper-dependent adenoviral vectors serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 96: 12816-12821.
Mujoo, K., Maneval, D. C., Anderson, S. C. & Gutterman, J. U. (1996) Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12, 1617-1623.
Muss,H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M. and Henderson, I. C. (1999) c-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260—1266.
Mymryk, J.S. (1996) Tumour suppressive properties of the adenovirus 5 E1A oncogene. Oncogene 13(8), 1581-9.
Nable GJ et al. (1993) Direct gene transfer with DNA—liposome com- plexes in melanoma: expression, biologic activity, and lack of onco-toxicity in humans. Proc Natl Acad Sci USA, 90: 11307— 11311.
Nakai, H., Storm, T. A. and Kay, M. A. (2000) Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nature Biotechnol. 18: 527-532.
Nicolson, G.L. (1988) Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim. Biophys. Acta 948, 175-224.
Nicolson, G.L. (1989) Metastatic tumor cell interactions with endothelium, basement membrane and tissue. Curr. Opin. Cell Biol. 1, 1009-19.
Niskanen, E., Blomqvist, C., Franssila, K., Hietanen, P. and Wasenius, V. M. (1997) Predictive value of c-erB-2, p53, cathepsin-D and histology of the primary tumor in metastatic breast cancer. Br. J. Cancer 76:917-922.
Nobel, G.J., et al. (1992) Clinical protocol : Immunotherapy of malignancy by in vivo gene transger into tumors. Human Gene Therapy 3, 399-410
Noonberg, S. B. and Benz, C. C. (2000) Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. [Review] Drugs. 59(4):753-67.
Noonberg, S. B., Scott, G. K., Hunt, C. A., Hogan, M. E. & Benz, C. C. (1994) Inhibition of transcription factor binding to the HER2 promoter by triple-forming oligodeoxyribonucleotides. Gene 149, 123-126.
Norton, P. A. & Coffin, J. M. (1985) Bacterial b-galactosidase as a marker of Rous sarcoma virus gene expression and replication. Mol. Cell. Biol. 5, 281-290.
Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., Hynes, N. E. (1998) ErbB1 and ErbB2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell Biol. 18: 5042-5051.
Onda, M., Matsuda, S., Higaki, S., Iijima, T., Fukushima, J., Yokokura, A., Kojima, T., Horiuchi, H., Kurokawa, T., and Yamamoto, T. (1996) ErbB-2 expression is correlated with poor prognosis for patients with osterosarcoma. Cancer 77:71-78.
Palowman, G. D., Green, J. M., Culouscou, J. M., Cariton, G. W., Rothwell, V. M. & Buckiey, S. (1993) Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 . Nature 366, 473-475.
Pandha HS, Martin L-A, Rigg A, Hurst HC, Stamp GWH, Sikara K and Lemoine NR. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. (1999). J. Clin. Oncol., 17, 2180 -2189.
Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., Wood, W. I., Parahadjopulos, D. and Benz, C. C. (1995) Development of anti- p185neu immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 92, 1327-1331.
Parker, S. E., Vahlsing, H. L., Serfilippi, L. M., Franklin, C. L., Doh, S. G., Gromkowski, S. H., Lew, D., Manthorpe, M., Norman, J. (1995) Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum. Gene Ther. 6: 575-590.
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., Graham, F. L. (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93; 13565-13570.
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. (1998) Phase II study of receptor-enhanced chemosensitivity using recom-binant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659—2671.
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J. and Slamon, D. J. (1997) The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in breast and ovarian cancercells. Oncogene 15:537-547.
Peles E, Lamprecht R, Ben-Levy R. (1992a) Regulated coupling of the neu receptor to phosphatidylinositol 3-kinase and its release by oncogenic activation. J. Biol. Chem. 267: 12266-12274.
Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B. and Yarden,Y. (1992b) Isolation of the Neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205-216.
Peles, E., Ben-Levy, R., Tzahar, E., Liu, N., Wen, D. and Yarden, Y. (1993) Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO Journal. 12(3):961-71.
Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., Eberlein, T. J. (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432—436.
Petit, C. A., Gardes, M., Feunteun, J. (1983) Immortalization of rodent embryo fibroblasts by SV40 is maintained by the A gene. Virology. 127(1):74-82.
Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. S. and Slamon, D. J. (1995) HER-2 tyrosin kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446.
Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B. and Slamon, D. J. (1994) Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells. Oncogene 9:1829-1838.
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A. and Slamon, D. J. (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER2 receptor and DNA-reactive grugs. Oncogene 17:2235-2249.
Pirollo, K. F., Hao, Z., Rait, A., Ho, E. W. and Chang, E. H. (1997) Evidence supporting a signal transduction in pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem. Biophys. Res. Commun. 230:196-201.
Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G. and Shoyab, M. (1993) Ligand-specific activation of HER4/p180 erbB4 , a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746—1750.
Plowman, G. D., Green , J. M., Culouson, J. M., Carlton, G. W., Rothwell, V. M. & Buckley, S. (1993) Heregulin induces tyrosine phosphorylation of HER4/p180 erbB4. Nature 366, 473-475.
Porter-Jordan, K. and Lippman, M. E. (1994) Overview of the biologic markers of breast cancer. Breast Cancer 8:73-100.
Qian, X., Levea, C. M., Freeman, J. K., Dougall, W. C. & Greene, M. I. (1994) Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kianse activation and transphosphorylation. Proc. Natl. Acad. Sci. USA 91, 1500-1504.
Rait, A. S., Pirollo, K. F., Rait, V., Krygier, J. E., Xiang, L., Chang, E. H. (2001) Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther 10: 728-39.
Rao, G. N., Ney, E. and Herbert, R. A. (1999) Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. Breast Cancer Res. Tret. 56: 241-254.
Rawins, D. R., Milman, G., Hayward, S. D. and Hayward, G. S. (1985) Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA1) to clustered site in the plasmid maintenance region. Cell. 42, 859-868.
Reddy, V. B. Thimmappaya, B., Dhar, R., Subramanian, K. N., Zain, B. S., Pan. J., Ghosh, P. K. Celma, M. L. & Weissman, S. M. (1978) The genome of simian virus 40. Science 200, 494-502.
Reddy, V.B., Thimmappaya, B., Dhar, R., Subramanian, K.N., Zain, B.S., Pan, J., Ghosh, P.K., Celma, M.L. and Weissman, S.M. (1978) The genome of simian virus 40. Science 200, 494-502.
Reedman, B. M. and Klein, G. (1973) Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell line. Int. J Cancer 11, 499-520.
Reese, D. M., and Slamon, D. J. (1997) HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells, 15: 1-8.
Reisman, D. and Sugden, B. (1986) trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Molecular & Cellular Biology. 6(11):3838-46, 1986
Repesh, L.A. (1989) A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9, 192-208.
Roh, H., Hirose, C. B., Boswell, C. B., Pippin, J. A., Drebin, J. A. (1999) Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery. 126(2):413-21.
Roh, H., Pippin, J., Boswell, C., Drebin, J. A. (1998) Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. Journal of Surgical Research. 77(1):85-90.
Roh, H., Pippin, J., Drebin, J. A. (2000) Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Research. 60(3):560-5.
Rowe, D. T., Evan, G. I., Wallace, L. E., Farrell, P. J. and Rickinson, A. B. (1986) Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigene in Burkitt''s lymphoma cell. EMBO J. 5, 2599-2607
Rozan, S., Vincent-Salomon, A., Zafrani, B., Validire, P., Decremoux, P., Bernoux, A., Nieruchalski, M., Fourquet, A., Clough, K., Dieras, V. et al. (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy. Int. J. Cancer 79:27-33.
Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C., Harris, R., Page, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., Jowett, A., Stables, J., Topley, P., Wood, E. R., Brignola, P. S., Kadwell, S. H., Reep, B. R., Mullin, R. J., Alligood, K. J., Keith, B. R., Crosby, R. M., Murray, D. M., Knight, W. B., Gilmer, T. M., Lackey, K. (2001) The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 61(19): 7196-203.
Russell, K. S. and Hung, M. C. (1992) Tra
第一頁 上一頁 下一頁 最後一頁 top